From MSC secretome to exosome injections and next-gen PRP alternatives, here is what 2026 research says about regenerative hair loss treatments — and who they work best for.
A 2026 meta-analysis pools 236 patients across 5 trials, and a 114-patient Phase 2 RCT shows MSC therapy achieves EASI-75 in 24% of severe AD patients. Exosome hydrogel delivery and batch consistency data now address the scalability questions that held this field back.
Three major clinical trials — including a 404-patient 3-year study — are finally giving us real data on whether MSC therapy works for chronic low back pain and degenerative disc disease. Here's what the evidence says, in plain language.
A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.
Our Bangkok clinic explores how MSC therapy is helping COPD patients breathe easier — reducing inflammation, reactivating lung stem cells, and improving quality of life.
Diabetic ED, post-prostatectomy ED, PDE5 non-responders — here’s what 2026 trials and clinical experience show for stem cell therapy: who is a candidate, what the procedure looks like, what it costs, and what to expect.
MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.
2026 medical update on MSC therapy for diabetic foot ulcers: M2 macrophage polarization, EXO-miR3671 angiogenesis, hydrogel delivery, UC-MSC vs ADSC head-to-head, 47-RCT meta-analysis, and cost-effectiveness vs amputation in Thailand.
2026 Q3 update on allogeneic vs autologous MSC: head-to-head trial data, donor-age impact, 2026 manufacturing advances, when each is preferred, the cost picture, and FAQ for patients in Thailand and Asia-Pacific.
2026 patient guide to MSC therapy for Alzheimer’s disease: how it differs from lecanemab and donanemab, who is a candidate, what outcomes to expect, the 6 active clinical trials including NCT06775964 and the first MSC + antibody drug combination trial.
French 
English 
Chinese 
Russian